Elizabeth Holland

Practice Areas

Elizabeth is Global Co-Head of IP Litigation.

She is a first-chair trial lawyer who focuses exclusively on representing innovators in patent infringement and related litigation in the life sciences space. With over 35 years of experience, Elizabeth has served as lead counsel in numerous patent infringement litigations, licensing disputes, arbitrations, IPR proceedings and Federal Circuit appeals. She has particular expertise in Hatch-Waxman and BPCIA litigation, as well as disputes between innovator companies.

Elizabeth is consistently ranked among the top lawyers in her field by publications such as Chambers Global, Chambers USA, IAM 1000 – The World's Leading Patent Practitioners, The Legal 500 U.S., Managing Intellectual Property, LMG Life Sciences and Euromoney, which have noted her “assured handling of even the most complex pharmaceuticals patent cases” and have described her as “exactly what you want in a first-chair lawyer; she is very skilled in the courtroom, very adept at managing multiple important cases, and well-liked by judges.”

Elizabeth has also been noted as being “exceptional on her feet in court;” getting “excellent results;” and “understanding clients’ business goals and litigating with those in mind.” She has thrice been named “Hatch Waxman Litigator of the Year” by LMG Life Sciences and has been featured as a “Winning Litigator” by the National Law Journal.

Elizabeth has successfully represented companies such as Novartis, Takeda, Wyeth, Celltrion, Ceva Sante, Enzymotec, and Boston Scientific in patent litigation in district courts throughout the United States, at the International Trade Commission, in post-grant proceedings before the PTAB, and at the Federal Circuit. She has also coordinated worldwide patent litigation, and has particular experience with courts in the UK, Netherlands, France, Israel, India and Mexico.

At her previous firms, Elizabeth served on the Executive, Management, and Partnership committees and chaired the Diversity, Equity + Inclusion Committee.